

HOLD TP: Rs 566 | △ 7%

DABUR INDIA

Consumer Staples

01 August 2025

Improving underlying trends but A&P needs to hold

- Compared to consensus, sales were inline but EBITDA 3% higher as
 A&P cuts more than offset the impact from commodity inflation
- Sales trends improved, with non-seasonal business volumes up 7% whole overall volumes grew 3%
- Dabur's FY26 target of HSD sales growth in achievable but margin targets appear stretched given risk to FY27 sales growth. Hold

Lokesh Gusain research@bobcaps.in

1QFY26 result summary: Both sales and EBITDA increased 2% on a YoY basis. Compared to consensus, sales were in line while EBITDA came in 3% higher with margins also 50bps higher. A&P was cut ~14% YoY which helped in offsetting commodity inflation. Dabur faced 7% inflation during the quarter which was largely offset with pricing and spending cuts.

Improving underlying sales: Excluding the impact from unseasonal rains / shorter summer; underlying sales trends improved. Total volumes were +3%, while with non-seasonal volume up 7%. Inventory days in General Trade also remained stable at 21-22 days. Net pricing was -2% as inflation offsetting pricing of 3%-4% was more than offset with incremental promos to distributor. International business grew 14% YoY on a constant FX basis.

FY26 outlook: Dabur expects HSD sales growth in FY26 with double digit sales growth in 2Q on a low base due to inventory correction in the last year. The company also expects "meaningful" margin expansion during the year. We forecast 8% growth on sales and 9% growth on EBITDA. While there may not be cuts to A&P on a YoY basis, we expect A&P as a percentage of sales to decline over FY26 to help offset inflationary pressures.

Our view – Dabur's target of high single digit sales growth is achievable given recent improvement and stable distributor inventory. However, its target of "meaningful" improvement in margins is unlikely without a considerable slowdown in business reinvestments. Slow spending over a period of one year can adversely impact sales growth trajectory. We value Dabur at 47x, in line with its 5Yr historical average P/E on 12m to March 2027 EPS. Our target price changes to Rs566 from Rs 538. Share price return of 7% – Hold

(Rs mn)	1Q25	1Q26	YoY (%)
Revenue	33,491	34,046	1.7
Adjusted EBITDA	6,550	6,678	2.0
EBITDA Margin (%)	19.6	19.6	6bps

Source: Company, Bloomberg, BOBCAPS Research

Key changes

Target	Rating
A	∢ ▶

Ticker/Price	DABUR IN/Rs 529
Market cap	US\$ 10.7bn
Free float	33%
3M ADV	US\$ 14.1mn
52wk high/low	Rs 672/Rs 433
Promoter/FPI/DII	66%/17%/17%

Source: NSE | Price as of 31 Jul 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	125,631	135,438	145,511
EBITDA (Rs mn)	23,164	25,153	27,655
Adj. net profit (Rs mn)	17,666	19,094	20,926
Adj. EPS (Rs)	10.0	10.8	11.8
Consensus EPS (Rs)	10.0	11.0	12.3
Adj. ROAE (%)	16.4	16.6	17.0
Adj. P/E (x)	53.1	49.1	44.8
EV/EBITDA (x)	40.8	37.6	34.1
Adj. EPS growth (%)	(4.1)	8.1	9.6

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





1QFY26 result review

Earnings revisions

- Sales Our sales growth is (1) revised upwards for FY26, (2) unchanged in FY27 and (2) revised downwards on FY28. The 14% A&P cut is concerning and continued lower A&P as a % of sales can impact volume growth. We keep our FY27 sales unchanged but reduce our FY28 forecast to account for some share losses due to falling A&P as a % of sales.
- Margins Our EBITDA margins are revised upwards across the forecast periods to account for pricing, and spending cuts.

Fig 1 - Dabur earnings revisions

(Rs mn)	Actual	New	Old	(%)	New	Old	(%)	New	Old	(%)
	FY25	FY26	FY26	Change	FY27	FY27	Change	FY28	FY28	Change
Sales	125,631	135,438	133,799	1.2	145,511	145,217	0.2	157,005	158,867	(1.2)
EBITDA	23,164	25,153	23,963	5.0	27,655	26,855	3.0	30,336	30,013	1.1
EBITDA Margin (%)	18.4	18.6	17.9	66bps	19.0	18.5	51bps	19.3	18.9	43bps
Adj. PAT	17,666	19,094	18,167	5.1	20,926	20,292	3.1	23,157	22,885	1.2
Adj. EPS	9.97	10.77	10.25	5.1	11.80	11.45	3.0	13.06	12.91	1.1

Source: Company, Bloomberg, BOBCAPS Research

Valuation

Dabur cut A&P meaningfully in 1QFY26 to manage margins. For the rest of the year, target is to improve margins meaningfully. While there may not be cuts to A&P on a YoY basis, we expect A&P as a % of sales to decline over FY26 to help offset inflationary pressures. This can adversely impact sales growth in FY27 and beyond. We forecast FY25-FY28 CAGR of 8% on sales and 9% on EBITDA.

Dabur is also looking to add high growth digital first type of businesses to its portfolio to drive volumes over the medium term. This should bode well subject t successful integration of the new business.

Dabur has traded at 5Yr average P/E of 47x on 1-year forward EPS. We value Dabur in line with its 5Yr historical average P/E on 12m to June 2027 EPS. Our target price changes to Rs566 from Rs538. Share price return of 7%. HOLD.

Risks

Key upside / downside risks to our estimates are:

- Decrease / increase in competitive intensity in beverages
- Faster / slower and stronger / weaker than expected recovery in rural
- Rebound / slowdown in urban consumption
- Fall / rise in raw material costs
- Currency appreciation / depreciation in key markets



Financials

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	124,040	125,631	135,438	145,511	157,005
EBITDA					
	24,002 3,992	23,164	25,153	27,655	30,336
Depreciation		4,456	4,380	4,557	4,847
EBIT	20,010	18,708	20,773	23,098	25,488
Net interest inc./(exp.)	(1,242)	(1,635)	(1,178)	(945)	(945)
Other inc./(exp.)	4,824	5,501	4,881	4,673	5,180
Exceptional items	0	0	0	0 00 005	00.700
EBT	23,593	22,574	24,476	26,825	29,723
Income taxes	5,474	5,175	5,648	6,170	6,836
Extraordinary items	0 (242)	0	0	0	(07.1
Min. int./Inc. from assoc.	(319)	(278)	(275)	(271)	(271
Reported net profit	18,427	17,666	19,094	20,926	23,157
Adjustments	0	0	0	0	(
Adjusted net profit	18,427	17,666	19,094	20,926	23,157
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	24,217	28,253	29,784	31,833	34,511
Other current liabilities	8,866	10,670	10,670	10,670	10,670
Provisions	1,773	2,157	2,157	2,157	2,157
Debt funds	11,581	7,301	8,301	8,301	8,301
Other liabilities	1,759	1,838	1,838	1,838	1,838
Equity capital	1,772	1,772	1,772	1,772	1,772
Reserves & surplus	101,259	110,330	115,543	126,862	139,432
Shareholders' fund	103,031	112,103	117,315	128,634	141,205
Total liab. and equities	151,227	162,323	170,066	183,435	198,683
Cash and cash eq.	2,476	1,843	4,715	13,646	23,439
Accounts receivables	8,987	8,885	10,155	10,882	11,846
Inventories	19,470	23,001	24,888	26,608	28,880
Other current assets	25,863	31,596	31,596	31,596	31,596
Investments	528	1,223	1,223	1,223	1,223
Net fixed assets	27,700	29,663	31,378	33,369	35,586
CWIP	0	0	01,070	00,000	00,000
Intangible assets	12,318	11,489	11,489	11,489	11,489
Deferred tax assets, net	0	0	0	0	11,400
Other assets	53,885	54,623	54,623	54,623	54,623
Total assets	151,227	162,323	170,066	183,435	198,683
10101 033013	101,221	102,020	110,000	100,400	130,000
Cash Flows					
Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	20,135	19,868	19,073	22,246	24,195
Capital expenditures	(5,639)	(5,695)	(6,095)	(6,548)	(7,065)
Change in investments	(7,978)	(3,093)	0	0	C
Other investing cash flows	3,899	4,297	3,953	3,785	4,196
Cash flow from investing	(9,717)	(4,491)	(2,141)	(2,763)	(2,869)
Equities issued/Others	0	3	0	0	C
Debt raised/repaid	(472)	(2,168)	1,000	0	C
Interest expenses	0	0	0	0	(
Dividends paid	(9,658)	(9,748)	(13,882)	(9,607)	(10,587
Other financing cash flows	(1,483)	(2,138)	(1,178)	(945)	(945
Cash flow from financing	(11,612)	(14,051)	(14,060)	(10,552)	(11,532
Chg in cash & cash eq.	(3,383)	4,567	2,872	8,931	9,793
Closing cash & cash eq.	2,476	1,843	4,715	13,646	23,439

Per Share					
Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	10.4	10.0	10.8	11.8	13.1
Adjusted EPS	10.4	10.0	10.8	11.8	13.1
Dividend per share	5.5	8.0	5.3	5.7	6.4
Book value per share	58.1	63.3	66.2	72.5	79.6
Valuations Ratios					
Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	7.6	7.5	7.0	6.5	6.0
EV/EBITDA	39.4	40.8	37.6	34.1	30.9
Adjusted P/E	50.9	53.1	49.1	44.8	40.5
P/BV	9.1	8.4	8.0	7.3	6.6
DuPont Analysis					
Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	78.1	78.3	78.0	78.0	77.9
Interest burden (PBT/EBIT)	117.9	120.7	117.8	116.1	116.6
EBIT margin (EBIT/Revenue)	16.1	14.9	15.3	15.9	16.2
Asset turnover (Rev./Avg TA)	86.2	80.1	81.5	82.3	82.2
Leverage (Avg TA/Avg Equity)	1.5	1.5	1.4	1.4	1.4
Adjusted ROAE	18.7	16.4	16.6	17.0	17.2
Ratio Analysis					
Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	7.6	1.3	7.8	7.4	7.9
EBITDA	10.9	(3.5)	8.6	9.9	9.7
Adjusted EPS	7.9	(4.1)	8.1	9.6	10.7
Profitability & Return ratios (%)					
EBITDA margin	19.4	18.4	18.6	19.0	19.3
EBIT margin	16.1	14.9	15.3	15.9	16.2
Adjusted profit margin	14.9	14.1	14.1	14.4	14.7
Adjusted ROAE	18.7	16.4	16.6	17.0	17.2
ROCE	17.9	15.7	16.7	17.0	17.2
Working capital days (days)					
Receivables	26	26	26	26	26
Inventory	112	119	123	124	124
			440	440	440
Payables	130	147	149	148	148
Payables Ratios (x)	130	147	149	148	148
•	2.5	2.3	2.2	2.1	2.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

1.4

16.1

0.1

1.5

11.4

0.1

1.6

17.6

0.1

1.7

24.4

0.1

1.9

27.0

0.1

Current ratio

Net interest coverage ratio

Adjusted debt/equity



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009





Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): DABUR INDIA (DABUR IN)



 $B-Buy,\,H-Hold,\,S-Sell,\,A-Add,\,R-Reduce$

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not

DABUR INDIA



provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.